172 related articles for article (PubMed ID: 36752338)
41. Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches.
Ala C; Joshi RP; Gupta P; Ramalingam S; Sankaranarayanan M
J Biomol Struct Dyn; 2024; 42(1):261-273. PubMed ID: 37061929
[TBL] [Abstract][Full Text] [Related]
42. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
Poonia P; Sharma M; Jha P; Chopra M
Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
[TBL] [Abstract][Full Text] [Related]
43.
Muthiah I; Rajendran K; Dhanaraj P; Vallinayagam S
J Biomol Struct Dyn; 2021 Aug; 39(13):4807-4815. PubMed ID: 32580684
[TBL] [Abstract][Full Text] [Related]
44. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
45. Design, synthesis, extra-precision docking, and molecular dynamics simulation studies of pyrrolidin-2-one derivatives as potential acetylcholinesterase inhibitors.
Gupta M; Kumar A; Prasun C; Nair MS; Kini SG; Yadav D; Nain S
J Biomol Struct Dyn; 2023; 41(13):6282-6294. PubMed ID: 35921217
[TBL] [Abstract][Full Text] [Related]
46. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach.
Agarwal S; Kashaw SK
J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248
[TBL] [Abstract][Full Text] [Related]
47. Pharmacophore-based virtual screening and
Roney M; Huq AKMM; Issahaku AR; Soliman MES; Hossain MS; Mustafa AH; Islam MA; Dubey A; Tufail A; Mohd Aluwi MFF; Tajuddin SN
J Biomol Struct Dyn; 2023; 41(21):12186-12203. PubMed ID: 36645141
[TBL] [Abstract][Full Text] [Related]
48. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
[TBL] [Abstract][Full Text] [Related]
49. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
[TBL] [Abstract][Full Text] [Related]
50. Identification of naphthyridine and quinoline derivatives as potential Nsp16-Nsp10 inhibitors: a pharmacoinformatics study.
Aldahham BJM; Al-Khafaji K; Saleh MY; Abdelhakem AM; Alanazi AM; Islam MA
J Biomol Struct Dyn; 2022 Jun; 40(9):3899-3906. PubMed ID: 33252031
[TBL] [Abstract][Full Text] [Related]
51. Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies.
Rehman ZU; Najmi A
J Biomol Struct Dyn; 2023 Sep; ():1-21. PubMed ID: 37707987
[TBL] [Abstract][Full Text] [Related]
52.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
53. Insight parameter drug design for human β-tryptase inhibition integrated molecular docking, QSAR, molecular dynamics simulation, and pharmacophore modelling studies of α-keto-[1,2,4]-oxadiazoles.
Yu CX; Tan JW; Rullah K; Imran S; Tham CL
J Biomol Struct Dyn; 2023; 41(22):12978-12996. PubMed ID: 36709457
[TBL] [Abstract][Full Text] [Related]
54. 3D pharmacophore-based virtual screening, docking and density functional theory approach towards the discovery of novel human epidermal growth factor receptor-2 (HER2) inhibitors.
Gogoi D; Baruah VJ; Chaliha AK; Kakoti BB; Sarma D; Buragohain AK
J Theor Biol; 2016 Dec; 411():68-80. PubMed ID: 27693363
[TBL] [Abstract][Full Text] [Related]
55. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
[TBL] [Abstract][Full Text] [Related]
56. Ligand-based design approach of potential Bcl-2 inhibitors for cancer chemotherapy.
Arakal NG; Sharma V; Kumar A; Kavya B; Devadath NG; Kumar SB; Murthy KT; Murahari M
Comput Methods Programs Biomed; 2021 Sep; 209():106347. PubMed ID: 34399152
[TBL] [Abstract][Full Text] [Related]
57. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
Hassan A; Arafa RK
J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545
[TBL] [Abstract][Full Text] [Related]
58. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
[TBL] [Abstract][Full Text] [Related]
59.
Rajagopal K; Kalusalingam A; Bharathidasan AR; Sivaprakash A; Shanmugam K; Sundaramoorthy M; Byran G
Molecules; 2023 May; 28(10):. PubMed ID: 37241915
[TBL] [Abstract][Full Text] [Related]
60. Deep Learning and Structure-Based Virtual Screening for Drug Discovery against NEK7: A Novel Target for the Treatment of Cancer.
Aziz M; Ejaz SA; Zargar S; Akhtar N; Aborode AT; A Wani T; Batiha GE; Siddique F; Alqarni M; Akintola AA
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
